2Warner FJ, Smith AI, Hooper NM,et al. Angiotensin-converting enzyme-2 : a molecular and cellular perspective[ J ]. Cell Mol Life Sci, 2004, 61 (21) :2704 -2713.
3Towler P, Staker B, Prasad SG,et al. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis [ J ]. J Biol Chem, 2004,279 ( 17 ) : 17996 - 18007.
4Leung PS. The peptide hormone angiotensin Ⅱ: its new functions in tissues and organs [ J ]. Curr Protein Pept Sci, 2004, 5 (4) : 267 - 273.
5Danilczyk U, Eriksson U, Oudit GY, et al. Physiological roles of angiotensin-converting enzyme 2 [ J ]. Cell Mol Life Sci, 2004,61 (21) : 2714 -2719.
6Yamamoto K, Ohishi M, Katsuya T, etal. Deletion of angiotensinconverting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin Ⅱ [ J ]. Hypertension, 2006, 47(4) : 718 -726.
7Huentelman M J, Grobe JL, Vazquez J,et al. Protection from angiotensin Ⅱ-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats[J]. Exp Physiol, 2005, 90(5) : 783 - 790.
8Goulter AB, Goddard M J, Allen JC, et al. ACE2 gene expression is up-regulated in the human failing heart [ J ]. BMC Med, 2004, 2 (1) : 19.
9Kitfleson MM, Minhas KM, Irizarry RA,et al. Gene expression analysis of ischemic and nonischemic cardiomyopathy: Shared and distinct genes in the development of heart failure [ J ]. Physiol Genomics, 2005, 21(3) : 299 -307.
10Burrell LM, Risvanis J, Kubota E, et al. Myocardial infarction increases ACE2. expression in rat and humans[J]. Eur Heart J,2005, 26(4) : 369 -375.
2McMurray JJ,Ostergren J,Swedberg K,et al.Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors:the CHARM-Added trial[J].Lancet.2003,362(9379):767-771.
3Solomon SD,Wang D,Finn P,et al.Effect of candesartan on cause-spectific mortality in heart failure patients:the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM)program.[J].Circulation,2004,110 (15):2180-2183.
4Pfeffer MA,McMurray JJ,Velazquez EJ,et al.Valsartan,captopril,or both in myocardial infarction complicated by heart failure,left ventricular dysfunction,or both[J].N Engl J Med,2003,349 (20):1893-1906.
5Mann DL,Deswal A.Angiotensin-receptor blockade in acute myocardial infarction-a matter of dose[J].N Engl J Med,2003,340(20):1963-1965.
6Antman EM,Anbe DT,Armstrong PW,et al.ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary:a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines(Uriting Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction)[J].Circulation,2004,110 (5):588-636.
6Lemos VS, Silva DM, Wahher T, et al. The endothelium-dependent vasodilator effect of the nonpeptide angiotensin (1-7) mimic AVE0991 is abolished in the aorta of Mas-knockout mice [ J ]. J Cardiovasc Phamacol, 2005, 46( 3 ) :274 - 279.
7Kostenis E, Milligan G, Christopoulos A, et al. G-protein-coupled receptor Mas is an physiological antagonist of the angiotensin II typel receptor [ J ]. Circulation, 2005, 111 ( 14 ) : 1806 - 1813.
8Sampain WO, Souza dos Santos RA, Faria-Silva R, et al. Angiotensin(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation Akt-dependent pathways [J].Hypertension, 2007, 49(1 ) :184 - 192.
9Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor [J]. Am J Physiol Heart Cire Physiol, 2005, 289 (4) : H1560 - H1566.
10Grobe JL, Mecca AP, Mao H, et al. Chronic Angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension [ J ]. Am J Physiol Heart Circ Physiol, 2006, 290 (6) : H2417 - H2423.
